Published in J Hematol Oncol on February 07, 2011
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget (2012) 1.34
Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov (2013) 1.33
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia (2014) 1.17
Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia. PLoS One (2013) 1.02
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med (2014) 0.97
Alternative expression of TCRζ related genes in patients with chronic myeloid leukemia. J Hematol Oncol (2012) 0.97
Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation. J Hematol Oncol (2013) 0.88
New insights into antigen specific immunotherapy for chronic myeloid leukemia. Cancer Cell Int (2012) 0.88
Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica (2014) 0.87
Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line. J Hematol Oncol (2011) 0.86
CD44 targets Wnt/β-catenin pathway to mediate the proliferation of K562 cells. Cancer Cell Int (2013) 0.83
Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2. PLoS One (2013) 0.83
Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms. Mol Cancer (2015) 0.82
Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias. PLoS One (2014) 0.81
Integrin VLA-5 and FAK are Good Targets to Improve Treatment Response in the Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Front Oncol (2014) 0.81
Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic Myelogenous Leukemia Patients With Imatinib Resistance. Iran J Cancer Prev (2015) 0.80
Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia. Genome Biol (2014) 0.80
Anti-tumor activity of Eurycoma longifolia root extracts against K-562 cell line: in vitro and in vivo study. PLoS One (2014) 0.79
Inhibition of 32Dp210 cells harboring T315I mutation by a novel derivative of emodin correlates with down-regulation of BCR-ABL and its downstream signaling pathways. J Cancer Res Clin Oncol (2014) 0.77
A screening-based approach to circumvent tumor microenvironment-driven intrinsic resistance to BCR-ABL+ inhibitors in Ph+ acute lymphoblastic leukemia. J Biomol Screen (2013) 0.77
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies. Oncotarget (2016) 0.77
Methylation analysis of the DAPK1 gene in imatinib-resistant chronic myeloid leukemia patients. Oncol Lett (2014) 0.76
Ursolic acid-mediated apoptosis of K562 cells involves Stat5/Akt pathway inhibition through the induction of Gfi-1. Sci Rep (2016) 0.76
Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target. Oncol Rep (2016) 0.75
DNA Repair-A Double-Edged Sword in the Genomic Stability of Cancer Cells-The Case of Chronic Myeloid Leukemia. Int J Mol Sci (2015) 0.75
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. Oncotarget (2017) 0.75
The exploration of network motifs as potential drug targets from post-translational regulatory networks. Sci Rep (2016) 0.75
KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors. Oncotarget (2016) 0.75
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. Leukemia (2016) 0.75
Growth of tyrosine kinase inhibitor-resistant Philadelphia-positive acute lymphoblastic leukemia: Role of bone marrow stromal cells. Oncol Lett (2017) 0.75
Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. Oncotarget (2016) 0.75
Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia. Genes Cancer (2016) 0.75
A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Leukemia (2016) 0.75
STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia. Leuk Suppl (2014) 0.75
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells. Oncotarget (2016) 0.75
Addressing intra-tumoral heterogeneity and therapy resistance. Oncotarget (2016) 0.75
mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL. Mol Cancer Ther (2017) 0.75
Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia. Mol Diagn Ther (2017) 0.75
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 20.30
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 8.86
Ras oncogenes: split personalities. Nat Rev Mol Cell Biol (2008) 7.91
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet (2004) 3.96
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia (2002) 3.90
Active transport of imatinib into and out of cells: implications for drug resistance. Blood (2004) 3.52
An expanding role for mTOR in cancer. Trends Mol Med (2005) 3.40
Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood (2000) 2.67
P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem (1996) 2.47
Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther (2005) 2.23
Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia (2009) 1.99
Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer (2010) 1.97
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood (1997) 1.96
Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res (2008) 1.56
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood (2000) 1.51
ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res (2005) 1.50
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia (2005) 1.48
CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res (2009) 1.38
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res (2008) 1.38
Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. Cancer Res (2010) 1.26
Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis. Leukemia (2008) 1.20
SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines. J Hematol Oncol (2009) 1.09
Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma (2008) 1.09
Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells. Oncogene (2008) 1.05
Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest (2008) 0.99
Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. Leuk Res (2009) 0.94
Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J (2005) 0.93
ABL-BCR expression in BCR-ABL-positive human leukemia cell lines. Leuk Res (1999) 0.89
Tumor suppression in T cell leukemia--the role of Ikaros. Leuk Res (2009) 0.89
Src kinases in Ph+ lymphoblastic leukemia. Nat Genet (2004) 0.85
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010) 7.96
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
Check your cultures! A list of cross-contaminated or misidentified cell lines. Int J Cancer (2010) 3.04
Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet (2012) 2.07
New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood (2008) 1.97
Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma. BMC Cancer (2010) 1.55
Amplification at 11q23 targets protein kinase SIK2 in diffuse large B-cell lymphoma. Leuk Lymphoma (2010) 1.54
Mix-ups and mycoplasma: the enemies within. Leuk Res (2002) 1.51
One falsehood leads easily to another. Int J Cancer (2008) 1.49
Comparative PCR analysis for detection of mycoplasma infections in continuous cell lines. In Vitro Cell Dev Biol Anim (2002) 1.45
Immunoprofiling of cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma. Leuk Res (2003) 1.44
Beware imposters: MA-1, a novel MALT lymphoma cell line, is misidentified and corresponds to Pfeiffer, a diffuse large B-cell lymphoma cell line. Genes Chromosomes Cancer (2013) 1.42
Establishment of novel B-cell precursor leukemia sister cell lines NALM-36 and NALM-37: shift of immunoglobulin phenotype to double light chain positive B-cell. Leuk Res (2002) 1.37
Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute lymphoblastic leukemia by remote 3'-BCL11B enhancers and coregulation by PU.1 and HMGA1. Cancer Res (2007) 1.34
Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int J Cancer (2002) 1.26
The cardiac homeobox gene NKX2-5 is deregulated by juxtaposition with BCL11B in pediatric T-ALL cell lines via a novel t(5;14)(q35.1;q32.2). Cancer Res (2003) 1.25
Expression of HOX genes in acute leukemia cell lines with and without MLL translocations. Leuk Lymphoma (2004) 1.22
The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood (2003) 1.22
Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification. Haematologica (2012) 1.20
Comparative antibiotic eradication of mycoplasma infections from continuous cell lines. In Vitro Cell Dev Biol Anim (2002) 1.16
Match criteria for human cell line authentication: where do we draw the line? Int J Cancer (2012) 1.10
Detection of mycoplasma contaminations. Methods Mol Biol (2005) 1.10
SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines. J Hematol Oncol (2009) 1.09
Comprehensive analysis of homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1. Blood (2007) 1.09
Cell line cross-contamination initiative: an interactive reference database of STR profiles covering common cancer cell lines. Int J Cancer (2010) 1.09
Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia. Leuk Lymphoma (2009) 1.07
Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia. Haematologica (2011) 1.06
Authentication of scientific human cell lines: easy-to-use DNA fingerprinting. Methods Mol Biol (2005) 1.05
Authentication of cancer cell lines by DNA fingerprinting. Methods Mol Med (2004) 1.03
Cytogenetic harvesting of commonly used tumor cell lines. Nat Protoc (2007) 1.03
Bladder carcinoma cell line ECV304 is not a model system for endothelial cells. In Vitro Cell Dev Biol Anim (2002) 1.02
Activation of HOX11L2 by juxtaposition with 3'-BCL11B in an acute lymphoblastic leukemia cell line (HPB-ALL) with t(5;14)(q35;q32.2). Genes Chromosomes Cancer (2003) 1.01
Detecting mycoplasma contamination in cell cultures by polymerase chain reaction. Methods Mol Biol (2011) 1.00
A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood (2014) 0.98
Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines. Mol Cancer (2010) 0.96
Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms. J Transl Med (2011) 0.95
Online verification of human cell line identity by STR DNA typing. Methods Mol Biol (2011) 0.94
Detecting Mycoplasma contamination in cell cultures by polymerase chain reaction. Methods Mol Med (2004) 0.93
Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia. Mol Cancer (2009) 0.93
Treatment of mycoplasma contamination in cell cultures with Plasmocin. J Biomed Biotechnol (2012) 0.93
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines. J Biomed Biotechnol (2010) 0.93
Detection of p53 gene mutations by single strand conformational polymorphism (SSCP) in human acute myeloid leukemia-derived cell lines. Leuk Res (2002) 0.93
Activation of HLXB9 by juxtaposition with MYB via formation of t(6;7)(q23;q36) in an AML-M4 cell line (GDM-1). Genes Chromosomes Cancer (2005) 0.92
Identification and verification of rodent cell lines by polymerase chain reaction. Cytotechnology (2007) 0.90
Eradication of mycoplasma contaminations. Methods Mol Biol (2005) 0.89
Mantle cell lymphoma-derived cell lines: unique research tools. Leuk Res (2006) 0.89
Elimination of mycoplasmas from infected cell lines using antibiotics. Methods Mol Biol (2011) 0.89
Mycoplasma contamination of murine embryonic stem cells affects cell parameters, germline transmission and chimeric progeny. Transgenic Res (2008) 0.89
Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines. AIDS (2010) 0.88
The necessity of identity assessment of animal intestinal cell lines: A case report. Cytotechnology (2011) 0.88
t(4;8)(q27;q24) in Hodgkin lymphoma cells targets phosphodiesterase PDE5A and homeobox gene ZHX2. Genes Chromosomes Cancer (2011) 0.88
Tumor necrosis factor receptor-associated factor (TRAF) 4 is a new binding partner for the p70S6 serine/threonine kinase. Leuk Res (2003) 0.88
Public repositories: users reluctant to give materials. Nature (2006) 0.87
A simple method using beta-globin polymerase chain reaction for the species identification of animal cell lines--a progress report. In Vitro Cell Dev Biol Anim (2004) 0.87
Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia. Leuk Lymphoma (2011) 0.86
Deregulated FOX genes in Hodgkin lymphoma. Genes Chromosomes Cancer (2014) 0.86
BCL11B rearrangements probably target T-cell neoplasia rather than acute myelocytic leukemia. Cancer Genet Cytogenet (2004) 0.86
STR DNA typing of human cell lines: detection of intra- and interspecies cross-contamination. Methods Mol Biol (2013) 0.86
Multiple mechanisms induce ectopic expression of LYL1 in subsets of T-ALL cell lines. Leuk Res (2009) 0.86
BCR-ABL1 expression in multiple myeloma cells: a case of mistaken identity? Proc Natl Acad Sci U S A (2013) 0.85
Transcriptional deregulation of homeobox gene ZHX2 in Hodgkin lymphoma. Leuk Res (2011) 0.85
The Wnt pathway destabilizes adherens junctions and promotes cell migration via β-catenin and its target gene cyclin D1. FEBS Open Bio (2012) 0.84
Aberrant lymphocyte enhancer-binding factor 1 expression is characteristic for sporadic Burkitt's lymphoma. Am J Pathol (2013) 0.84
Cytogenetic analysis of cancer cell lines. Methods Mol Biol (2011) 0.84
Genomic imbalances in drug-resistant T-cell acute lymphoblastic CEM leukemia cell lines. Blood Cells Mol Dis (2002) 0.84
t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5. PLoS One (2013) 0.83
Stable expression of MutLγ in human cells reveals no specific response to mismatched DNA, but distinct recruitment to damage sites. J Cell Biochem (2013) 0.83
Induction of CD28 on the new myeloma cell line MOLP-8 with t(11;14)(q13;q32) expressing delta/lambda type immunoglobulin. Leuk Res (2004) 0.83
Activation of Paired-homeobox gene PITX1 by del(5)(q31) in T-cell acute lymphoblastic leukemia. Leuk Lymphoma (2011) 0.82
NK-like homeodomain proteins activate NOTCH3-signaling in leukemic T-cells. BMC Cancer (2009) 0.82
DNA methylation regulates expression of VEGF-R2 (KDR) and VEGF-R3 (FLT4). BMC Cancer (2012) 0.82
Persistent use of misidentified cell lines and its prevention. Genes Chromosomes Cancer (2002) 0.81
Multicolor-FISH analysis of a natural killer cell line (NK-92). Leuk Res (2002) 0.80
Transcriptional activation of prostate specific homeobox gene NKX3-1 in subsets of T-cell lymphoblastic leukemia (T-ALL). PLoS One (2012) 0.80
Malignant hematopoietic cell lines: in vitro models for the study of erythroleukemia. Leuk Res (2004) 0.79
Granulocyte-macrophage colony-stimulating factor: inhibitor of tumor necrosis factor-induced apoptosis. Leuk Res (2003) 0.79
Chromothripsis in Hodgkin lymphoma. Genes Chromosomes Cancer (2013) 0.79
The NADPH oxidase inhibitor imipramine-blue in the treatment of Burkitt lymphoma. Mol Cancer Ther (2014) 0.79
Repressed BMP signaling reactivates NKL homeobox gene MSX1 in a T-ALL subset. Leuk Lymphoma (2014) 0.79
Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 questions their origin from hairy cell leukemia. Blood (2012) 0.79
CD7 in acute myeloid leukemia: correlation with loss of wild-type CEBPA, consequence of epigenetic regulation. J Hematol Oncol (2010) 0.79
Where have all the cell lines gone? Int J Cancer (2012) 0.78
Oncogenic deregulation of NKL homeobox gene MSX1 in mantle cell lymphoma. Leuk Lymphoma (2014) 0.78
Detection of mycoplasma contaminations. Methods Mol Biol (2013) 0.78
A novel sporadic Burkitt lymphoma cell line (BLUE-1) with a unique t(6;20)(q15;q11.2) rearrangement. Leuk Res (2006) 0.78
Human leukemia and lymphoma cell lines as models and resources. Curr Med Chem (2008) 0.78
Elimination of Mycoplasma from infected cell lines using antibiotics. Methods Mol Med (2004) 0.78
Transcription factor expression in cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma. Hum Cell (2004) 0.78